



## Mavacamten for Hypertrophic Cardiomyopathy: Effectiveness and Value

Friday • October 22, 2021 • 9:00 am – 3:00 pm PT

Virtual Event – Zoom Webinar

[https://us02web.zoom.us/webinar/register/WN\\_Rdj0QNEdTNSJ85QnS-crQ](https://us02web.zoom.us/webinar/register/WN_Rdj0QNEdTNSJ85QnS-crQ)

Time (PT)	Activity
9:00 am – 9:20 am	<b>Meeting Convened and Opening Remarks</b> Steven D. Pearson, MD, MSc, President, ICER
9:20 am – 10:00 am	<b>Presentation of the Clinical Evidence</b> Jason H. Wasfy, MD, MPhil, Medical Director, Mass General Physician’s Organization, Massachusetts General Hospital
10:00 am – 10:40 am	<b>Presentation of the Economic Model</b> Surrey M. Walton, PhD, Associate Professor, University of Illinois at Chicago College of Pharmacy
10:40 am – 10:50 am	<b>Manufacturer Comments and Discussion</b>
10:50 am – 11:15 am	<b>Public Comments and Discussion</b>
11:15 am – 11:25 am	<b>Break</b>
11:25 am – 12:15 pm	<b>CTAF Vote on Clinical Effectiveness and Value</b>
12:15 pm – 1:00 pm	<b>Lunch Break</b>
1:00 pm – 2:30 pm	<b>Policy Roundtable</b>
2:30 pm – 3:00 pm	<b>Reflections from CTAF</b>
3:00 pm	<b>Meeting Adjourned</b>

ICER Staff and Consultants	
<b>Molly Beinfeld, MPH</b> , Senior Research Lead, Evidence Synthesis, ICER*	<b>David Rind, MD, MSc</b> , Chief Medical Officer, ICER*
<b>Laura Cianciolo</b> , Program Manager, ICER*	<b>Jyotirmoy Sarker, MPharm, MBA, MBiotech</b> , Graduate Student, Pharmacy Systems, Outcomes, and Policy, University of Illinois at Chicago*
<b>Maggie Houle</b> , Program and Event Coordinator, ICER*	<b>Surrey M. Walton, PhD, MA</b> , Professor, Pharmacy Systems, Outcomes, and Policy; Assistant Director, Center for Pharmacoepidemiology and Pharmacoeconomic Research, University of Illinois at Chicago*
<b>Emily Nhan</b> , Research Assistant, ICER*	<b>Jason H. Wasfy, MD, MPhil</b> , Associate Professor, Harvard Medical School; Medical Director, Massachusetts General Hospital Physicians Organization; Director of Outcomes Research, Massachusetts General Hospital Heart Center*
<b>Rasheed Mohammed, PharmD, MPH</b> , Health Technology Assessment Fellow, ICER*	<b>Melanie Whittington, PhD</b> , Associate Director of Health Economics, ICER*
<b>Steven D. Pearson, MD, MSc</b> , President, ICER	

\*No conflicts of interest to disclose, defined as individual health care stock ownership in any health plan or pharmaceutical, biotechnology, or medical device manufacturers, or any health care consultant income or honoraria from health plans or manufacturers.

Participating Members of CTAF	
<b>Ralph G. Brindis, MD, MPH, MACC, FSCAI, FAHA</b> , Clinical Professor of Medicine, UCSF*	<b>Elizabeth J. Murphy, MD, DPhil</b> , Professor of Clinical Medicine, UCSF; Chief, Division of Endocrinology and Metabolism, Zuckerberg San Francisco General Hospital*
<b>Felicia Cohn, PhD</b> , Bioethics Director, Kaiser Permanente, Orange County; Clinical Professor of Bioethics, Department of Medicine, University of California, Irvine School of Medicine*	<b>Kathryn A. Phillips, PhD</b> , Professor of Health Economics and Health Services Research; Director and Founder, UCSF Center for Translational and Policy Research on Personalized Medicine; Department of Clinical Pharmacy/School of Pharmacy, UCSF Institute for Health Policy Studies, and UCSF Comprehensive Cancer Center*
<b>Robert Collyar</b> , Patient Advocate in Research*	<b>Rita F. Redberg, MD, MSc, FACC</b> , Cardiologist and Professor of Medicine and Women’s Cardiovascular Services at UCSF*
<b>Kimberly Gregory, MD, MPH</b> , Vice Chair, Women’s Healthcare Quality & Performance Improvement, Cedars-Sinai Medical Center*	<b>Richard Seiden, JD</b> , Patient Advocate, Retired Partner, Foley & Lardner LLP*
<b>Paul Heidenreich, MD, MS</b> , Professor of Medicine, Stanford University School of Medicine*	<b>Alexander Smith, MD, MPH</b> , Professor of Medicine, UCSF
<b>Jeffrey Hoch, PhD</b> , Associate Director, Center for Healthcare Policy and Research, UC Davis*	<b>Joanna Smith, LCSW, MPH, CHA</b> , Chief Executive Officer, Healthcare Liaison, Inc.*
<b>Sei Lee, MD</b> , Associate Professor of Medicine, Division of Geriatrics, UCSF*	<b>Anthony Sowry</b> , Patient Advocate and Lead Volunteer, California, National Patient Advocate Foundation; Senior Vice President, Maritime Container Shipping (Retired)*
<b>Joy Melnikow, MD</b> , Director of the Center for Healthcare Policy and Research and Professor of Family and Community Medicine at UCD*	

\*No conflicts of interest to disclose, defined as individual health care stock ownership (including anyone in the member’s household) in any company with a product under study, including comparators, at the meeting in excess of \$10,000 during the previous year, or any health care consultancy income from the manufacturer of the product or comparators being evaluated.

Policy Roundtable Participant	Conflict of Interest
<p><b>Milind Desai, MD, MBA</b>, Director of Clinical Operations, Hypertrophic Cardiomyopathy Center, Cleveland Clinic</p>	<p>Dr. Desai served as an investigator for the VALOR study of mavacamten sponsored by Bristol Myers Squibb/MyoKardia.</p>
<p><b>Martin Maron, MD</b>, Director, Hypertrophic Cardiomyopathy Center and Research Institute, Tufts Medical Center</p>	<p>Dr. Maron served as a site investigator for a Phase I study of mavacamten and currently serves as a steering committee member for a Phase II study of a second-generation myosin inhibitor sponsored by Cytokinetics.</p>
<p><b>Gwendolyn Mayes, JD, MMSc</b>, Founder and Chief Concept Officer, GwenCo Health</p>	<p>Gwendolyn Mayes serves as a consultant to the Hypertrophic Cardiomyopathy Association, which receives 20% of its sponsorship for educational programming from Bristol Myers Squibb/MyoKardia. She also consults for Edwards Lifesciences, Paragonix, and Natural Cycles.</p>
<p><b>Carla McSpadden, RPh, BCGP, MBA</b>, Director, Clinical Formulary Strategies, Humana</p>	<p>Carla McSpadden is a full-time employee of Humana.</p>
<p><b>Lisa Salberg</b>, Founder and CEO, Hypertrophic Cardiomyopathy Association</p>	<p>The Hypertrophic Cardiomyopathy Association receives 20% of its sponsorship for educational programming from Bristol Myers Squibb/MyoKardia.</p>
<p><b>John Watkins, PharmD, MPH, BCPS</b>, Residency Program Director, Premera Blue Cross</p>	<p>John Watkins is a full-time employee of Premera Blue Cross.</p>